FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

19 letters match. Newest first.

  1. Green Vitality dba Gr33n

    FDA warned Green Vitality dba Gr33n that its Jimerito Honey Eye Drops are an unapproved new drug sold with disease-treatment claims.

    High risk
  2. My Holistic Honey c/o Shenzhen Qanhai Wanb Express Supply Chain Co., LTD

    FDA warned My Holistic Honey that its honey eye drops are an unapproved new drug sold with drug claims.

    High risk
  3. Homeopathic Educational Services dba Homeopathic Family Medicine

    FDA says Homeopathic Family Medicine sells unapproved Cineraria Maritima Eye Drops for cataracts online.

    High risk
  4. Mel Honey US

    FDA warned Mel Honey US that its Jimerito (Melipona) Honey eye drops are an unapproved new drug.

    High risk
  5. Supply Center USA

    Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.

    High risk
  6. Trew Balance

    FDA warned Trew Balance that its Trew Vision CBD Eye Drops are an unapproved new drug sold with disease-treatment claims.

    High risk
  7. Life Enthusiast Co-op

    FDA tells Life Enthusiast Co-op its three eye products sold online are unapproved new drugs.

    High risk
  8. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  9. Scope Health Inc

    FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.

    High risk
  10. EyeTech One, LLC

    FDA warns EyeTech One that its EYELIVIO lubricant eye ointment is an unapproved new drug and misbranded.

    Medium
  11. OSRX, Inc.

    OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.

    High risk
  12. Regenerative Processing Plant, LLC

    FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.

    High risk
  13. Velocity Pharma LLC

    Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.

    High risk
  14. Optikem International Inc.

    FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.

    High risk
  15. Amazon.com, Inc.

    FDA warned Amazon for selling seven unapproved eye drug products on Amazon.com.

    High risk
  16. Similasan AG

    Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.

    High risk
  17. K.C. Pharmaceuticals Inc.

    FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.

    High risk
  18. Pharmedica USA, LLC

    FDA found Pharmedica made ophthalmic and nasal drugs under insanitary conditions without required sterile controls.

    High risk
  19. Sterling Pharmaceutical Services, LLC

    Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.

    High risk